症状前GRN携带者5年随访中的脑代谢特征
前瞻性队列研究(Predict-PGRN)纳入80人,分析58人(27例症状前GRN携带者与31例非携带者),随访5年。携带者在预期发病约15年前即出现左侧颞上沟低代谢,无显著皮层萎缩;随后5年右侧颞上沟代谢下降最明显(p<0.001),年化代谢下降为-1.37%,高于对照组的-0.21%(p=0.004)。
要点
- 症状前GRN携带者在预期发病约15年前出现左侧颞上沟低代谢,无显著皮层萎缩
- 随访5年右侧颞上沟代谢下降最明显(p<0.001),无显著体积丢失
- 携带者年化代谢下降-1.37%,高于对照组的-0.21%(p=0.004)
核心结论
- 研究在症状前GRN携带者中检测到颞上沟区域脑代谢改变,早于结构和认知改变,有助于刻画临床前GRN疾病的病理时间线。
- 颞上沟参与面部交流线索的感知,其功能障碍可能促成额颞叶痴呆特征性的社会认知缺陷。
- 研究支持脑代谢改变作为早期疾病追踪生物标志物,并提出年化百分比下降作为未来试验中监测治疗反应的指标。
研究设计与样本
- 前瞻性队列研究(Predict-PGRN),聚焦GRN疾病,对参与者进行5年纵向评估。
- 纳入80人,58人(27例症状前GRN携带者与31例非携带者)纳入分析。
- 评估包括认知/行为评估、血浆神经丝蛋白测定、脑MRI和FDG-PET。
- 各时间点进行两组间基于体素的结构与代谢影像比较;纵向PET变化采用基于体素比较和代谢年化百分比变化法评估。
- 分析区域脑代谢与血浆神经丝蛋白及认知变化的相关性。
主要发现
- 横断面比较显示症状前GRN携带者左侧颞上沟区域(涵盖颞中回和颞上回)显著低代谢,约在预期发病前15年,无显著皮层萎缩。
- 随后5年纵向代谢下降在携带者右侧颞上沟附近最明显(p<0.001),与对照组相比无显著更大的体积丢失。
- 携带者估计年化代谢下降为-1.37%,高于对照组的-0.21%(p=0.004)。
- 症状前GRN携带者中,较低葡萄糖摄取与较高神经丝蛋白升高(p=0.003)及较低额叶认知评分(p=0.014)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: GRN variants are a frequent cause of familial frontotemporal dementia (FTD). Monitoring disease progression in asymptomatic carriers of genetic variants is a major challenge in delivering preventative therapies before clinical onset. This study aimed to assess the usefulness of fluorodeoxyglucose (FDG)-PET in identifying metabolic changes in presymptomatic GRN carriers (PS-GRN+) and to trace their longitudinal progression. METHODS: Participants were longitudinally evaluated over 5 years in a prospective cohort study focused on GRN disease (Predict-PGRN). They underwent cognitive/behavioral assessment, plasma neurofilament measurement, brain MRI, and FDG-PET. Voxel-wise comparisons of structural and metabolic imaging data between 2 groups were performed for each time point. Longitudinal PET changes were evaluated with voxel-wise comparisons and the metabolic percent annual changes method. The association of regional brain metabolism with plasma neurofilament and cognitive changes was analyzed. RESULTS: Among the 80 individuals enrolled in the study, 58 (27 PS-GRN+ and 31 noncarriers) were included in the analyses. Cross-sectional comparisons between PS-GRN+ and controls found a significant hypometabolism in the left superior temporal sulcus (STS) region (encompassing the middle and superior temporal gyri), approximately 15 years before the expected disease onset, without significant cortical atrophy. The longitudinal metabolic decline over the following 5 years peaked around the right STS in carriers (p < 0.001), without significantly greater volume loss compared with that in controls. Their estimated annualized metabolic decrease (-1.37%) was higher than that in controls (-0.21%, p = 0.004). Lower glucose uptake was associated with higher neurofilament increase (p = 0.003) and lower frontal cognitive scores (p = 0.014) in PS-GRN+. DISCUSSION: This study detected brain metabolic changes in the STS region, preceding structural and cognitive alterations, thus contributing to the characterization of the pathochronology of preclinical GRN disease. Owing to the STS involvement in the perception of facially communicated cues, it is likely that its dysfunction contributes to social cognition deficits characterizing FTD. Overall, our study highlights brain metabolic changes as an early disease-tracking biomarker and proposes annualized percent decrease as a metric to monitor therapeutic response in forthcoming trials.
引用
- Saracino D, Sellami L, Boniface H, et al. Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up. Neurology. 2022. PMID: 36257714. doi:10.1212/WNL.0000000000201439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。